Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

The FDA explains that that dosing errors tend to be main factor ... those made with the experimental drug Retatrutide and those made with salt forms of semaglutide. “These salt forms, including ...

Retatrutide is a synthetic peptide, which research indicates functions as a triple agonist for type 2 diabetes and weight loss. Peptides, small chains of amino acids, have been hypothesized to ...